Hematologic

Viewing Page 3 of 7 | Showing Results 21 - 30 of 63

Phase 1/2 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma

Inclusion Criteria:Subjects of ≥ 18 years of age with any of the following:For Dose-Escalation cohorts:Fimepinostat + venetoclax:...

Krish Patel, M.D.
  • Swedish Medical Center

A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.Inclusion Criteria:• Subject...

William Bensinger, M.D.
  • Swedish Medical Center

CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY

The purpose of the Connect MDS/AML Disease Registry is to provide unique insights into treatment regimens and sequencing of these regimens as they...

James Cunningham, M.D.
  • Providence St. Mary Regional Cancer Center
  • Walla Walla Research

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)

This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who...

John Godwin, M.D.
  • Providence Cancer Institute Franz Clinic

Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias

Inclusion Criteria:Participant must have relapsed/refractory AML and exhausted standard available therapies known to provide clinical...

Raya Mawad, M.D.
  • Swedish Medical Center

cHL Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

The purpose of this study is to gather data on patients diagnosed with and treated for classical Hodgkin Lymphoma (cHL). It aims to closely observe...

Ajay Kundra, M.D.
  • Providence Regional Cancer Partnership - Everett

Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed or Refractory Multiple Myeloma.Key Inclusion Criteria:Diagnosis of...

William Bensinger, M.D.
  • Swedish Medical Center

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma

Inclusion Criteria:Relapsed or refractory hematologic malignancy (lymphoma or multiple myeloma) that has progressed, or is currently progressing...

Krish Patel, M.D.
  • Swedish Medical Center
Viewing Page 3 of 7 | Showing Results 21 - 30 of 63